Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Autoimmune Partnering Deal Trends, Players and Financials 2010-2016 - Research and Markets

Research and Markets
Posted on: 06 Oct 16

Research and Markets has announced the addition of the "Global Autoimmune Partnering 2010-2016: Deal trends, players and financials" report to their offering.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report includes coverage of the following autoimmune diseases:

  • Multiple sclerosis
  • Restless leg syndrome
  • Eczema
  • Alopecia
  • Psoriasis
  • Celiac disease
  • Inflammatory bowel disease
  • Crohn's disease
  • Ulcerative colitis
  • Glomerulonephritis
  • Endometriosis
  • Immune thrombocytopenic purpura
  • Neutropenia
  • Graft versus host disease
  • Scleroderma
  • Systemic lupus erythematosus
  • Addison's disease
  • Diabetes Type 1
  • Ankylosing spondylitis
  • Juvenile arthritis
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Uveitis
  • Narcolepsy
  • Idiopathic pulmonary fibrosis
  • Sarcoidosis
  • Meniere's disease

Global Autoimmune Partnering 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Autoimmune deal trends since 2010
  • Access Autoimmune deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Autoimmune partner companies
  • Comprehensive access to over 500 links to actual Autoimmune deals entered into by the world's biopharma companies
  • Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Autoimmune opportunities
  • Uncover companies actively partnering Autoimmune opportunities

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking

Chapter 3 - Financial deal terms for Autoimmune partnering

Chapter 4 - Leading Autoimmune deals and dealmakers

Chapter 5 - Autoimmune contract document directory

Chapter 6 - Autoimmune dealmaking by therapeutic target

For more information about this report visit

View source version on

Business Wire

Last updated on: 06/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.